EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery

Glioblastoma is the most aggressive malignant brain tumor among all primary brain and central nervous system tumors. The median survival time for glioblastoma patients given the current standard of care treatment (surgery, radiation, and chemotherapy) is less than 15 months. Thus, there is an urgent...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Xuhui, Pastan, Ira, Bigner, Darell D., Chandramohan, Vidyalakshmi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341612/
https://www.ncbi.nlm.nih.gov/pubmed/28286803
http://dx.doi.org/10.14800/rci.1430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341612/
https://www.ncbi.nlm.nih.gov/pubmed/28286803
http://dx.doi.org/10.14800/rci.1430

Ejemplares similares